Nor Consult, LLC Employee Directory
Research ServicesWashington, United States11-50 Employees
Nor Consult, LLC stands at the forefront of biometric consulting, delivering expert guidance and innovative solutions to the life sciences sector. With a deep-rooted commitment to scientific rigor and regulatory excellence, Nor Consult partners with organizations across the globe to advance research, development, and regulatory approval in cardiovascular, cardiorenal, medical device, orthopedic, spine, spinal cord, infectious disease and other domains. Led by a distinguished professor and former FDA reviewer, Nor Consult leverages a unique blend of academic insight, regulatory acumen, and industry experience. Our team’s expertise is grounded in decades of hands-on involvement in clinical research, regulatory strategy, and statistical analysis, making us a trusted partner for both established global medical companies and emerging biotech innovators. At Nor Consult, our mission is to empower our clients to make data-driven decisions that accelerate innovation, ensure patient safety, and achieve regulatory success. We believe that robust biometric strategies are the cornerstone of impactful medical advancements, and we are dedicated to providing the highest level of scientific and regulatory support. Areas of Expertise Nor consult has contributed to the design, analysis, and regulatory submission of Phase 1-4, feasibility, pilot and pivotal clinical trials for novel therapeutics, combination products and devices targeting breast cancer, chronic kidney disease, degenerative disc disease, hypertension, osteoarthritis, spinal cord injury, weight loss and dozens of other indications. Our expertise encompasses: Statistical design and analysis of clinical trials. Real World Evidence (RWE) generation and analysis Integration of digital health technologies, wearables, biomarkers and surrogate endpoints Regulatory strategy and submission support, including preparation of statistical analysis plans (SAPs), clinical study reports (CSRs), and responses to regulatory agencies